Defence to Present New Scientific Data on Its ADC-Enhancing Accum Technology at the World ADC Conference in San Diego, USA, November 4-5, 2025
Montreal, Quebec--(Newsfile Corp. - October 23, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a leading biotechnology company specialized in drug delivery technologies, is pleased to announce that it will present new scientific data highlighting the performance of its Accum® technology in enhancing the efficacy of antibody-drug conjugates (ADCs) at the 16th World ADC Conference in San Diego, CA, USA
Biotechnology, Pharmaceuticals, Health
2025-10-23 3:15 AM EDT | Defence Therapeutics Inc.
Bachem Announces Progress in Building K Start-Up and Expansion of Its Site in Vista, CA
Bubendorf, Switzerland--(Newsfile Corp. - October 23, 202
Biotechnology, Chemical, Healthcare and Hospitals, Pharmaceuticals
2025-10-23 1:01 AM EDT | Bachem Holding AG
Hemostemix Granted Trademark "KNOW YOUR HEALTH" in Japan, International Registration No. 1744775 Covers Stem Cell Preparations and Research in Classes 1, 5, 42
Calgary, Alberta--(Newsfile Corp. - October 22, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's own) stem cell therapy company offering VesCell™ (ACP-01) to no-option individuals suffering from angina, peripheral arterial disease, chronic limb threatening ischemia, ischemic cardiomyopathy, non-ischemic dilated cardiomyopathy, congestive heart failure, and total body ischemia, is pleased to announce that the Government of Japan has
Biotechnology, Pharmaceuticals, Health
2025-10-22 10:04 AM EDT | Hemostemix Inc.
Shuttle Pharmaceuticals to Acquire AI Molecular Modeling and Predictive Analytics Platform
Rockville, Maryland--(Newsfile Corp. - October 21, 2025) - Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) ("Shuttle" or the "Company") today announced that it has entered into a binding term sheet with 1542770 BC Ltd. ("Molecule"), a Canadian artificial intelligence company specializing in molecular discovery and drug development technologies. Under the terms of the agreement, Shuttle or one of its affiliates will acquire substantially all of Molecule's as
2025-10-21 4:05 PM EDT | Shuttle Pharmaceuticals Holdings Inc.
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
King of Prussia, Pennsylvania--(Newsfile Corp. - October 21, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will present an update on the company's proprietary INTASYL siRNA technology and progress on the on-going clinical t
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-10-21 7:45 AM EDT | Phio Pharmaceuticals Corp.
Optimi Health Provides Corporate Update
Vancouver, British Columbia--(Newsfile Corp. - October 21, 2025) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Canadian manufacturer of pharmaceutical psychedelics including MDMA and naturally-derived psilocybin, is pleased to announce that it has passed its Drug Establishment Licence (DEL) inspection by Health Canada, with no critical observations, resulting in a GMP-compliant rating for the fabrication and distribution of phar
Biotechnology, Pharmaceuticals, Health, Psychedelics
2025-10-21 7:00 AM EDT | Optimi Health Corp.
TempraMed Announces Private Placement of up to C$2.5 Million
Vancouver, British Columbia--(Newsfile Corp. - October 21, 2025) - TempraMed Technologies Ltd. (CSE: VIVI) ("TempraMed" or the "Company") is pleased to announce a non-brokered private placement (the "Offering") of up to 3,289,473 units of the Company (each, a "Unit") at a price of C$0.76 per Unit for aggregate gross proceeds of up to C$2,500,000. Each Unit will consist of one common share of the Company (each, a "Share") and one Share purcha
Technology, Biotechnology, Pharmaceuticals, Health
2025-10-21 7:00 AM EDT | TempraMed Technologies Ltd
Republic Technologies Inc. Announces Up to US$100 Million Proposed Secured Convertible Note Facility Financing
Vancouver, British Columbia--(Newsfile Corp. - October 20, 2025) - Republic Technologies Inc. (CSE: DOCT) (FSE: 7FM0) (WKN: A41AYF) (the "Company" or "Republic") is pleased to announce that it proposes to enter into a financing agreement with an institutional investor (the "Investor") for a proposed secured convertible note facility of up to US$100 million (the "Proposed Convertible Facility") (the "Proposed Financing"), featuring an init
Technology, Pharmaceuticals, Health
2025-10-20 12:59 PM EDT | Republic Technologies Inc.
Republic Technologies Inc. kündigt geplante gesicherte Wandelanleihefazilität in Höhe von bis zu 100 Mio. USD an
Vancouver, British Columbia--(Newsfile Corp. - Montag, 20. Oktober 2025) - Republic Technologies Inc. (CSE: DOCT) (FSE: 7FM0) (WKN: A41AYF) ("das Unternehmen" oder "Republic") freut sich bekanntzugeben, dass es beabsichtigt, mit einem institutionellen Investor ("der Investor") eine Finanzierungsvereinbarung über eine geplante gesicherte Wandelanleihefazilität von bis zu 100 Mio. US-Dollar ("die geplante Wandelanleihefazilität") ("die geplante Finanzierung")
Technology, Pharmaceuticals, Health
2025-10-20 9:55 AM EDT | Republic Technologies Inc.
Republic Technologies Inc. Announces Up to US$100 Million Proposed Secured Convertible Note Facility Financing
Vancouver, British Columbia--(Newsfile Corp. - October 20, 2025) - Republic Technologies Inc. (CSE: DOCT) (FSE: 7FM0) (WKN: A41AYF) (the "Company" or "Republic") is pleased to announce that it proposes to enter into a financing agreement with an institutional investor (the "Investor") for a proposed secured convertible note facility of up to US$100 million (the "Proposed Convertible Facility") (the "Proposed Financing"), featuring an initial US
Technology, Pharmaceuticals, Health
2025-10-20 9:20 AM EDT | Republic Technologies Inc.
PreveCeutical Provides Update on Plan of Arrangement with BioGene Therapeutics Inc.
Vancouver, British Columbia--(Newsfile Corp. - October 20, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce that, further to its News Releases of September 4, 2025, September 19, 2025 and October 10, 2025, it will be proceeding to complete its previou
Biotechnology, Pharmaceuticals, Health
2025-10-20 7:00 AM EDT | PreveCeutical Medical Inc.
PharmaTher Applauds FDA's Commissioner's National Priority Voucher (CNPV) Selection of Ketamine; Company Highlights Potential Ketamine Opportunity, 505(b)(2) Focus, and Upside from Strategic ANDA Sale
Toronto, Ontario--(Newsfile Corp. - October 17, 2025) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher"), a specialty life sciences company focused on unlocking the pharmaceutical potential of ketamine, today applauds the U.S. Food and Drug Administration's ("FDA") announcement on October 16, 2025 of the first-ever recipients of the new Commissioner's National Priority Voucher ("CNPV") pilot program, which include "ketamine for domestic manufacturing of a
Biotechnology, Pharmaceuticals
2025-10-17 8:26 AM EDT | PharmaTher Holdings Ltd.
Conexeu Sciences Closes Maximum $5M Reg CF Financing
Reno, Nevada--(Newsfile Corp. - October 16, 2025) - Conexeu Sciences Inc. (the "Company" or "Conexeu") a biotechnology company revolutionizing tissue regeneration, is pleased to announce the completion of its $5 million Regulation Crowdfunding (Reg CF) financing. Conexeu secured commitments in excess of $5 million in less than two weeks from the date of launching the financing through the Equifund platform.
Healthcare and Hospitals, Pharmaceuticals, Health
2025-10-16 9:01 AM EDT | Conexeu Sciences Inc.
InMed Pharmaceuticals Appoints Mr. John Bathery to Its Board of Directors
Vancouver, British Columbia--(Newsfile Corp. - October 16, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced the appointment of Mr. John Bathery to its Board of Directors, effective immediately. Mr. Bathery brings more than 30 years of experience in the pharmaceutical industry, including over 15 yea
Biotechnology, Pharmaceuticals
2025-10-16 8:30 AM EDT | InMed Pharmaceuticals
PharmaTher Advances Phase 3 FDA Package for Ketamine in LID-Parkinson's Disease
Toronto, Ontario--(Newsfile Corp. - October 16, 2025) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher"), a specialty life sciences company focused on unlocking the pharmaceutical potential of ketamine, today announced that it has begun preparing its U.S. Food and Drug Administration ("FDA") briefing materials to discuss a Phase 3 program for ketamine in levodopa-induced dyskinesia in Parkinson's disease ("LID-PD") and that prospective pharma partn
Biotechnology, Pharmaceuticals
2025-10-16 8:00 AM EDT | PharmaTher Holdings Ltd.
Hemostemix Adds the Treatment of Refractory Angina to Its Phase 1 Basket Protocol
Calgary, Alberta--(Newsfile Corp. - October 15, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's own) stem cell therapy company offering VesCell™ (ACP-01) to no-option individuals suffering from angina, peripheral arterial disease, chronic limb threatening ischemia, ischemic cardiomyopathy, non-ischemic dilated cardiomyopathy, congestive heart failure, and total body ischemia, in Florida under Florida's SB 1768, is pleased to annou
Biotechnology, Pharmaceuticals, Health
2025-10-15 3:51 PM EDT | Hemostemix Inc.
PharmaTher Announces KetAImine(TM) - AI Discovery Platform to Expand the Ketamine Portfolio, Enable Earlier Partnering, and Fast-Track 505(b)(2) NDA Filings
Toronto, Ontario--(Newsfile Corp. - October 15, 2025) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher"), a specialty life sciences company focused on unlocking the pharmaceutical potential of ketamine, today announced KetAImine™, a proprietary ketamine repurposing and discovery platform designed to create, prioritize, and de-risk new ketamine indications and combination therapies across therapeutic areas—forming a scalable pipeline for
Biotechnology, Pharmaceuticals
2025-10-15 8:00 AM EDT | PharmaTher Holdings Ltd.
Kiora Pharmaceuticals to Participate in the 2025 Maxim Growth Summit and Eyecelerator @ AAO 2025
Encinitas, California--(Newsfile Corp. - October 15, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) today announced that it will participate in an ophthalmology panel at the upcoming 2025 Maxim Growth Summit in New York and give an overview of its development pipeline at Eyecelerator @ AAO 2025 in Orlando. Maxim Growth Summit Ophthalmology Panel Details Title: A vision of innovation; Advances in biotechnology have spurred innovation in the manageme
Biotechnology, Pharmaceuticals
2025-10-15 7:00 AM EDT | Kiora Pharmaceuticals, Inc.
TempraMed to Commence Trading on the Canadian Securities Exchange Under Symbol "VIVI", Today, October 15, 2025
Vancouver, British Columbia--(Newsfile Corp. - October 15, 2025) - TempraMed Technologies Ltd. (CSE: VIVI) ("TempraMed" or the "Company") is pleased to announce that it has received approval to list its common shares (the "Common Shares") on the Canadian Securities Exchange ("CSE"). Trading is expected to commence on CSE under symbol "VIVI" at the open of markets on October 15, 2025. Further, the board of directors (the "Board") of the Compa
Technology, Biotechnology, Pharmaceuticals, Health
2025-10-15 7:00 AM EDT | TempraMed Technologies Ltd
CBIH Announces Women-First Fertility Innovation Built on Nanoemulsion Delivery
Houston, Texas--(Newsfile Corp. - October 13, 2025) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH) today announced the addition of a patent-pending nanoemulsion formulation to its growing portfolio, developed to support female fertility and reproductive function in women of advanced maternal age (35+). CBIH believes this innovation should expand evidence-based options for patients and partners. As age is a key determinant of reproductive outcomes—and first births
Biotechnology, Pharmaceuticals, Cannabis, Health
2025-10-13 7:00 AM EDT | Cannabis Bioscience International Holdings